Literature DB >> 22134119

Culture of human corneal endothelial cells isolated from corneas with Fuchs endothelial corneal dystrophy.

Karine Zaniolo1, Cristina Bostan, Olivier Rochette Drouin, Alexandre Deschambeault, Marie-Claude Perron, Isabelle Brunette, Stéphanie Proulx.   

Abstract

The purpose of this study was to assess the feasibility of initiating primary cultures of corneal endothelial cells from patients suffering from Fuchs endothelial corneal dystrophy (FECD; MIM# 1036800). We also evaluated which conditions yielded the best results for culture. Twenty-nine patients undergoing Descemet stripping automated endothelial keratoplasty consented to the use of their excised Descemet's membrane for this study. Out of the 29 specimens, 18 successfully initiated a culture. Cell morphology varied between endothelial (rounded, slightly elongated cells, n = 12) and fibroblastic-like (thin and very elongated cells, n = 6). These differences in cell morphology were also observed with the normal human corneal endothelial cell cultures. The cultures that initially presented an endothelial morphology maintained their shape in subcultures. Clusterin expression was similar in FECD and normal endothelial cells. Transmission electron microscopy of FECD Descemet's membranes showed a high degree of various abnormalities generally found in this disease, such as a thickened Descemet's membrane, presence of a posterior banded layer, presence of a fibrillar layer and striated bodies of various sizes and periodicities. Patient's age was predictive of culture success, all younger FECD donors generating cultures of endothelial morphology. The absence of a fibrillar layer was also a factor associated with greater success. Culture success was not dependent on specimen size, specimen pigmentation, or patient's preoperative central corneal thickness. In conclusion, this paper shows for the first time that central Descemet's membranes of patients suffering from FECD possess proliferative endothelial cells that can be isolated and cultured without viral transduction, opening the way for new in vitro studies of this disease.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22134119     DOI: 10.1016/j.exer.2011.10.018

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  6 in total

1.  Existence of Neural Crest-Derived Progenitor Cells in Normal and Fuchs Endothelial Dystrophy Corneal Endothelium.

Authors:  Kishore Reddy Katikireddy; Thore Schmedt; Marianne O Price; Francis W Price; Ula V Jurkunas
Journal:  Am J Pathol       Date:  2016-09-14       Impact factor: 4.307

2.  What does the future hold for the treatment of Fuchs endothelial dystrophy; will 'keratoplasty' still be a valid procedure?

Authors:  M Bruinsma; C M Tong; G R J Melles
Journal:  Eye (Lond)       Date:  2013-07-12       Impact factor: 3.775

3.  DNA damage and repair in Fuchs endothelial corneal dystrophy.

Authors:  Piotr Czarny; Ewelina Kasprzak; Mariusz Wielgorski; Monika Udziela; Beata Markiewicz; Janusz Blasiak; Jerzy Szaflik; Jacek P Szaflik
Journal:  Mol Biol Rep       Date:  2012-12-29       Impact factor: 2.316

Review 4.  Fuchs endothelial corneal dystrophy: The vicious cycle of Fuchs pathogenesis.

Authors:  Stephan Ong Tone; Viridiana Kocaba; Myriam Böhm; Adam Wylegala; Tomas L White; Ula V Jurkunas
Journal:  Prog Retin Eye Res       Date:  2020-05-08       Impact factor: 21.198

5.  Extracellular Matrix and Integrin Expression Profiles in Fuchs Endothelial Corneal Dystrophy Cells and Tissue Model.

Authors:  Benjamin Goyer; Mathieu Thériault; Sébastien P Gendron; Isabelle Brunette; Patrick J Rochette; Stéphanie Proulx
Journal:  Tissue Eng Part A       Date:  2017-09-28       Impact factor: 3.845

6.  Proliferation of Human Corneal Endothelia in Organ Culture Stimulated by Wounding and the Engineered Human Fibroblast Growth Factor 1 Derivative TTHX1114.

Authors:  David Eveleth; Sarah Pizzuto; Jessica Weant; Jennifer Jenkins-Eveleth; Ralph A Bradshaw
Journal:  J Ocul Pharmacol Ther       Date:  2020-07-28       Impact factor: 2.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.